Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.75 EUR | +0.16% | +1.78% | -3.87% |
May. 07 | Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025 | CI |
Apr. 26 | Orion Corporation Announces Appointments to Nomination Committee | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The firm trades with high earnings multiples: 21.91 times its 2024 earnings per share.
- With an enterprise value anticipated at 3.81 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.87% | 5.77B | A- | ||
+34.35% | 693B | C+ | ||
+29.39% | 584B | B | ||
-3.49% | 372B | C+ | ||
+20.15% | 332B | B- | ||
+6.19% | 294B | C+ | ||
+14.11% | 239B | B+ | ||
-3.03% | 211B | A+ | ||
+10.02% | 210B | B- | ||
+9.21% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ORNBV Stock
- Ratings Orion Oyj